Rheumatology

300.3K Papers

Follow See full results

Review Rheumatology

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

Yoshiya Tanaka, Yiming Luo, John J. O'Shea, Shingo Nakayamada

Summary: This Review discusses the therapeutic use of Janus kinase inhibitors in autoimmune rheumatic diseases, highlighting their disease-specific mechanisms of action. JAK inhibitors suppress intracellular signaling mediated by multiple cytokines, offering potential treatment options for a range of immune and inflammatory disorders.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Review Rheumatology

Synovial inflammation in osteoarthritis progression

Elsa Sanchez-Lopez, Roxana Coras, Alyssa Torres, Nancy E. Lane, Monica Guma

Summary: This review focuses on the biology of the synovium in osteoarthritis, including the interactions and activation of synovial cells, as well as their role in the progression of the disease.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Laura C. Coates, Enrique R. Soriano, Nadia Corp, Heidi Bertheussen, Kristina Callis Duffin, Cristiano B. Campanholo, Jeffrey Chau, Lihi Eder, Daniel G. Fernandez-Avila, Oliver FitzGerald, Amit Garg, Dafna D. Gladman, Niti Goel, Philip S. Helliwell, M. Elaine Husni, Deepak R. Jadon, Arnon Katz, Dhruvkumar Laheru, John Latella, Ying-Ying Leung, Christine Lindsay, Ennio Lubrano, Luis Daniel Mazzuoccolo, Philip J. Mease, Denis O'Sullivan, Alexis Ogdie, Wendy Olsder, Penelope Esther Palominos, Lori Schick, Ingrid Steinkoenig, Maarten de Wit, D. A. van der Windt, Arthur Kavanaugh

Summary: This article presents evidence-based treatment recommendations for Psoriatic Arthritis (PsA) medication selection, covering various clinical domains, related conditions and comorbidities. It provides important guidance and support for clinicians and individuals with PsA.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Prevalence Trends of Site-Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019

Huibin Long, Qiang Liu, Heyong Yin, Kai Wang, Naicheng Diao, Yuqing Zhang, Jianhao Lin, Ai Guo

Summary: The prevalence of osteoarthritis (OA) has steadily increased worldwide over the past decades, with geographic diversity and variation in affected joints. Knee OA contributes the most to the overall burden, while hip OA has the highest increasing rate in most regions. Prevention and early treatment are essential in mitigating the growing burden of OA.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3

Lauren A. Henderson, Scott W. Canna, Kevin G. Friedman, Mark Gorelik, Sivia K. Lapidus, Hamid Bassiri, Edward M. Behrens, Kate F. Kernan, Grant S. Schulert, Philip Seo, Mary Beth F. Son, Adriana H. Tremoulet, Christina VanderPluym, Rae S. M. Yeung, Amy S. Mudano, Amy S. Turner, David R. Karp, Jay J. Mehta

Summary: This study provides guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C) and hyperinflammation during COVID-19. The guidance was developed through expert consensus and includes 41 guidance statements and flow diagrams for the diagnosis and initial treatment of MIS-C.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial

Richard A. Furie, Gustavo Aroca, Matthew D. Cascino, Jay P. Garg, Brad H. Rovin, Analia Alvarez, Hilda Fragoso-Loyo, Elizabeth Zuta-Santillan, Thomas Schindler, Paul Brunetta, Cary M. Looney, Imran Hassan, Ana Malvar

Summary: This study compared the efficacy of obinutuzumab with standard therapies and placebo in the treatment of LN. The results showed that obinutuzumab achieved better complete renal responses at 52 and 104 weeks compared to standard therapies alone. It also showed improvements in other renal response measures, serologies, estimated glomerular filtration rate and proteinuria. Obinutuzumab was well tolerated and no new safety signals were identified.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update

Josef S. Smolen, Robert B. M. Landewe, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L. Hyrich, Janet E. Pope, Savia de Souza, Tanja A. Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L. Winthrop, Alejandro Balsa, Joan M. Bathon, Maya H. Buch, Gerd R. Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A. den Broeder, Khadija El Aoufy, Axel Finckh, Joao Eurico Fonseca, Jacques-Eric Gottenberg, Espen A. Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B. McInnes, Eduardo F. Mysler, Peter Nash, Gyula Poor, Gorica G. Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P. M. Vliet Vlieland, Rene Westhovens, Desiree van der Heijde

Summary: This study provides an update on the management recommendations for rheumatoid arthritis (RA) based on the latest developments in the field. The recommendations cover various aspects including medication use, combination therapy, treatment strategies, and dose reduction. The consensus was reached on 5 overarching principles and 11 specific recommendations.

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Article Rheumatology

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

Peter C. Grayson, Cristina Ponte, Ravi Suppiah, Joanna C. Robson, Anthea Craven, Andrew Judge, Sara Khalid, Andrew Hutchings, Raashid A. Luqmani, Richard A. Watts, Peter A. Merkel

Summary: The revised classification criteria for EGPA demonstrate strong performance characteristics and are validated for use in research.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Letter Rheumatology

COVID-19 in Italian patients with rheumatic autoimmune systemic diseases

Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Poupak Fallahi, Alessandro Antonelli

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Article Rheumatology

Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry

Pedro M. Machado, Saskia Lawson-Tovey, Anja Strangfeld, Elsa F. Mateus, Kimme L. Hyrich, Laure Gossec, Loreto Carmona, Ana Rodrigues, Bernd Raffeiner, Catia Duarte, Eric Hachulla, Eric Veillard, Eva Strakova, Gerd R. Burmester, Gozde Kubra Yardimci, Jose A. Gomez-Puerta, Julija Zepa, Lianne Kearsley-Fleet, Ludovic Trefond, Maria Cunha, Marta Mosca, Martina Cornalba, Martin Soubrier, Nicolas Roux, Olivier Brocq, Patrick Durez, Richard Conway, Tiphaine Goulenok, Johannes W. J. Bijlsma, Iain B. McInnes, Xavier Mariette

Summary: The study included 5121 participants from 30 countries, with 90% having I-RMD and 10% having NI-RMD. The majority of patients received the Pfizer/BioNTech vaccine. Breakthrough infections were rare, with 0.7% in I-RMD patients and 1.1% in NI-RMD patients. Adverse events were reported in 37% of cases, with serious AEs in 0.5%. This study concludes that the safety profiles of SARS-CoV-2 vaccines in patients with I-RMD were reassuring.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

METTL3-mediated m6A modification of ATG7 regulates autophagy-GATA4 axis to promote cellular senescence and osteoarthritis progression

Xiang Chen, Wang Gong, Xiaoyan Shao, Tianshu Shi, Lei Zhang, Jian Dong, Yong Shi, Siyu Shen, Jianghui Qin, Qing Jiang, Baosheng Guo

Summary: This study revealed the significant increase of senescent FLSs with OA progression, impacting autophagy and SASP expression. METTL3 negatively regulated autophagy-related genes, promoting FLS senescence. Inhibiting METTL3 could attenuate FLS senescence, offering a potential therapeutic strategy for OA.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Article Rheumatology

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study

Ingrid Jyssum, Hassen Kared, Trung T. Tran, Anne T. Tveter, Sella A. Provan, Joseph Sexton, Kristin K. Jorgensen, Jorgen Jahnsen, Grete B. Kro, David J. Warren, Eline B. Vaage, Tore K. Kvien, Lise-Sofie H. Nissen-Meyer, Ane Marie Anderson, Gunnveig Grodeland, Espen A. Haavardsholm, John Torgils Vaage, Siri Mjaaland, Silje Watterdal Syversen, Fridtjof Lund-Johansen, Ludvig A. Munthe, Guro Lovik Goll

Summary: This study investigates the humoral and cellular immune responses in rheumatoid arthritis patients treated with rituximab after receiving two or three doses of SARS-CoV-2 vaccines. The study finds that some patients do not have serological responses to two doses of the vaccine, but a third dose can enhance the cellular immune response. This is important for understanding the vaccine efficacy in immunocompromised patients.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis

Joanna C. Robson, Peter C. Grayson, Cristina Ponte, Ravi Suppiah, Anthea Craven, Andrew Judge, Sara Khalid, Andrew Hutchings, Richard A. Watts, Peter A. Merkel, Raashid A. Luqmani

Summary: The study aimed to develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Through consensus methodology and data analysis, 10 criteria items were identified and assigned weights for GPA diagnosis. The criteria demonstrated high sensitivity and specificity in the validation set, making them suitable for research purposes.

ANNALS OF THE RHEUMATIC DISEASES (2022)

添加到收藏夹

Meeting Abstract Rheumatology

ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update

Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert Landewe, Filip Van den Bosch, Boryana Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, Floris van Gaalen, Pal Geher, Lianne Gensler, Josef Hermann, Manouk de Hooge, Marketa Husakova, Uta Kiltz, Clementina Lopez-Medina, Pedro Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compan, Michael Nissen, Fernando Pimentel-Santos, Denis Poddubnyy, Fabian Proft, Martin Rudwaleit, Mark Telkman, Sizheng Zhao, Nelly Ziade, Desiree van der Heijde

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B. M. Landewe, Filip E. Van den Bosch, Boryana Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, Floris A. van Gaalen, Pal Geher, Lianne Gensler, Josef Hermann, Manouk de Hooge, Marketa Husakova, Uta Kiltz, Clementina Lopez-Medina, Pedro M. Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compan, Michael J. Nissen, Fernando M. Pimentel-Santos, Denis Poddubnyy, Fabian Proft, Martin Rudwaleit, Mark Telkman, Sizheng Steven Zhao, Nelly Ziade, Desiree van der Heijde

Summary: The ASAS-EULAR recommendations provide updated guidance on the management of axial spondyloarthritis, including treatment targets, non-pharmacological interventions, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) as the first-line pharmacological treatment. For patients with comorbidities, the use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is recommended. The recommendations also cover the management of extramusculoskeletal manifestations, tapering of bDMARDs, and surgical interventions.

ANNALS OF THE RHEUMATIC DISEASES (2023)

添加到收藏夹

Article Orthopedics

Epidemiology of osteoarthritis

K. D. Allen, L. M. Thoma, Y. M. Golightly

Summary: This narrative review summarizes the current evidence on the prevalence, incidence, and risk factors of osteoarthritis (OA) at the person-level and joint-level. The review highlights the high prevalence of OA worldwide, with older individuals, women, certain racial and ethnic groups, and individuals with lower socioeconomic status being more affected. Obesity and joint injury are identified as modifiable risk factors with the strongest evidence. Other emerging topics with potential associations with OA risk or progression include specific vitamins and diets, high blood pressure, genetic factors, metformin use, bone mineral density, abnormal joint shape and malalignment, and lower muscle strength/quality. The review also emphasizes the heterogeneity of OA and the importance of understanding and defining OA phenotypes. Overall, OA is a prevalent condition with significant global impacts on health outcomes, necessitating efforts to mitigate obesity and joint injury risks.

OSTEOARTHRITIS AND CARTILAGE (2022)

添加到收藏夹

Review Rheumatology

SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis

Richard Conway, Alyssa A. Grimshaw, Maximilian F. Konig, Michael Putman, Ali Duarte-Garcia, Leslie Yingzhijie Tseng, Diego M. Cabrera, Yu Pei Eugenia Chock, Huseyin Berk Degirmenci, Eimear Duff, Bugra Han Egeli, Elizabeth R. Graef, Akash Gupta, Patricia Harkins, Bimba F. Hoyer, Arundathi Jayatilleke, Shangyi Jin, Christopher Kasia, Aneka Khilnani, Adam Kilian, Alfred H. J. Kim, Chung Mun Alice Lin, Candice Low, Laurie Proulx, Sebastian E. Sattui, Namrata Singh, Jeffrey A. Sparks, Herman Tam, Manuel F. Ugarte-Gil, Natasha Ung, Kaicheng Wang, Leanna M. Wise, Ziyi Yang, Kristen J. Young, Jean W. Liew, Rebecca Grainger, Zachary S. Wallace, Evelyn Hsieh

Summary: This study indicates that individuals with rheumatic and musculoskeletal diseases (RMDs) have a higher risk of SARS-CoV-2 infection and an increased mortality rate compared to those without RMDs.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Rheumatology

Long-term use of immunosuppressive medicines and in-hospital COVID-19 outcomes: a retrospective cohort study using data from the National COVID Cohort Collaborative

Kathleen M. Andersen, Benjamin A. Bates, Emaan S. Rashidi, Amy L. Olex, Roslyn B. Mannon, Rena C. Patel, Jasvinder Singh, Jing Sun, Paul G. Auwaerter, Derek K. Ng, Jodi B. Segal, Brian T. Garibaldi, Hemalkumar B. Mehta, G. Caleb Alexander

Summary: This study found that the use of immunosuppressive medications in hospitalized COVID-19 patients was associated with a reduced risk of invasive ventilation, but overall no association with in-hospital death. Some medication classes may be associated with an increased risk of death for specific diseases, such as rituximab for rheumatological disease and cancer. Careful medication selection is needed for COVID-19 patients with long-term immunosuppression.

LANCET RHEUMATOLOGY (2022)

添加到收藏夹

Review Rheumatology

A new immunometabolic perspective of intervertebral disc degeneration

Vera Francisco, Jesus Pino, Miguel Angel Gonzalez-Gay, Francisca Lago, Jaro Karppinen, Osmo Tervonen, Ali Mobasheri, Oreste Gualillo

Summary: Studies have found that immunometabolic alterations in patients with obesity and type 2 diabetes mellitus are closely related to intervertebral disc degeneration, involving the abnormal production of proteins such as adipokines and exacerbation of inflammatory responses.

NATURE REVIEWS RHEUMATOLOGY (2022)

添加到收藏夹

Review Orthopedics

Osteoarthritis year in review 2021: epidemiology & therapy

J. G. Quicke, P. G. Conaghan, N. Corp, G. Peat

Summary: This article reviews research themes and individual studies in the clinical osteoarthritis field, including COVID-19, disease burden, occupational risk, prediction models, etc. Important findings include the impact of non-steroidal anti-inflammatory drugs on COVID-19 related deaths, the increasing incidence rate of OA, and the relationship between cartilage thickness loss and pain.

OSTEOARTHRITIS AND CARTILAGE (2022)

添加到收藏夹

«
1
2
3
4
5
»

See full results

Related Categories

Anesthesiology (212.5K) Audiology & Speech-Language Pathology (1.7K) Clinical Neurology (1.3M) Critical Care Medicine (338.4K) Dentistry, Oral Surgery & Medicine (340.8K) Dermatology (413.6K) Emergency Medicine (142.9K) Endocrinology & Metabolism (751.7K) Gastroenterology & Hepatology (856.4K) Geriatrics & Gerontology (226.3K) Gerontology (158.2K) Health Care Sciences & Services (433.8K) Hematology (653.3K) Immunology (896.7K) Infectious Diseases (453.2K) Integrative & Complementary Medicine (99.8K) Medical Ethics (26.6K) Medical Informatics (100.5K) Medical Laboratory Technology (108K) Medicine, General & Internal (1.3M) Medicine, Legal (48.4K) Medicine, Research & Experimental (710K) Nursing (297.8K) Obstetrics & Gynecology (559.8K) Oncology (1.8M) Ophthalmology (452.2K) Orthopedics (359.5K) Otorhinolaryngology (166K) Pediatrics (655.3K) Peripheral Vascular Disease (595.7K) Pharmacology & Pharmacy (1.3M) Primary Health Care (59.2K) Psychiatry (755.1K) Radiology, Nuclear Medicine & Medical Imaging (799.4K) Rehabilitation (249.2K) Surgery (1.3M) Toxicology (333.1K) Transplantation (309.7K) Tropical Medicine (112.2K) Urology & Nephrology (567K) Veterinary Sciences (455.3K)

© Peeref 2019-2024. All rights reserved.